The brain uptake of LAPDZ formulation was improved with quintuplet t 1/2. LAPDZ formulation showed half-life (t 1/2), volume of distribution (Vd) and clearance (Cl) as 5.53 ± 0.40 h -1, 0.129 ± 0.02 L, 0.015 ± 0.002 L/h, respectively.
Promising pharmacokinetic parameters were observed in animals treated with LAPDZ. Swiss albino mice exhibited enhanced brain uptake of LAPDZ administered via intravenous route. LAPDZ formulations inhibited acetylcholinesterase approximately by 82%, significantly higher ( p < 0.05) than plain DZ (30%). The drug was released in a sustained manner till 120 h in phosphate buffer saline (pH 7.4) and acid phthalate buffer (pH 4.0). Result: The size of prepared nanocomposites was 53.7 ± 4.0 to 137.7 ± 11.0 nm. Methods: In the present study, laponite (LAP) nanocomposites were exploited for the improved brain delivery of donepezil (DZ) following encapsulation approach due to their nano-size and positive charge at pH <9. Significance: Based on the outcomes of this study and taking into consideration of the unique characteristics of laponite, it can be further explored to deliver many other central nervous system acting drugs. During the past few years, development of novel delivery system has attracted considerable attention of formulation scientists to overcome the permeability limitation caused by BBB. Objective: Brain drug delivery for effective treatment of neurodegenerative disorders is limited due to the selective permeability of blood brain barrier (BBB).
0 kommentar(er)
